Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
304 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04944563 | Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field | recruiting | N/A | 1,120 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT05291052 | Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical University |
| 1 |
| Mar 22, 2022 |
| clinicaltrials |
| NCT05200312 | A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma(ZR2-CHOP) | unknown | Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05186558 | Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL | unknown | Phase 2 | 54 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT04956146 | Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer | unknown | Phase 2 | 46 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05231863 | Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study | unknown | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT04176913 | Study of LUCAR-20S in Patients With R/R NHL | terminated | Phase 1 | 7 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT03629873 | Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects | unknown | Phase 2 | 69 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05166070 | An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors | recruiting | Early Phase 1 | 24 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT05112523 | The Performance of Cancer Risk Genes in the Necessity of Secondary TURBT(RE-TURBT) | unknown | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 9, 2021 | clinicaltrials |
| NCT03486678 | SHR-1210 in Combination With GEMOX in Patients With Advanced BTC | completed | Phase 2 | 38 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT05096533 | The Application Value of Artificial Intelligence in MRI Precision Diagnosis and Treatment of Bladder Cancer | unknown | — | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT04718701 | Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer(ATNPA) | unknown | Phase 2 | 53 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04846452 | Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC | unknown | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04717531 | Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04899128 | Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer | unknown | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT04624711 | Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer | unknown | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT04588168 | Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma | unknown | N/A | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04502680 | Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients(EMBRAVE-001) | unknown | Phase 2 | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 11, 2020 | clinicaltrials |
| NCT04297202 | SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma(HCC-009) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT04453423 | Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer. | unknown | Phase 2 | 90 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 1, 2020 | clinicaltrials |
| NCT04432402 | Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma | unknown | N/A | 124 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT04385316 | Clinical Study of Gastric Cancer, Colorectal Cancer and Bladder Cancer Based on Liquid Biopsy | unknown | — | 3 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT04143048 | A Study on Non-invasive Early Diagnosis of Gastrointestinal Stromal Tumors and Differentiation of Benign and Malignant Nodules | unknown | — | 300 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 11, 2020 | clinicaltrials |
| NCT04295109 | Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function | unknown | N/A | 105 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT04351321 | The Safety of Totally Laparoscopic Versus Laparoscopy-Assisted Total Gastrectomy. | unknown | N/A | 560 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Apr 17, 2020 | clinicaltrials |
| NCT02891642 | Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid | unknown | — | 1,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT03190616 | Apatinib in Refractory Colorectal Cancer | completed | Phase 2 | 54 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT04211896 | Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer | unknown | Phase 2 | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Dec 26, 2019 | clinicaltrials |
| NCT04026100 | CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | unknown | Phase 1 | 9 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03769805 | Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC(CSOAIMTOAN) | unknown | N/A | 83 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT04094051 | Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice | unknown | — | 580 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT04091906 | PBMC Donation in UCAR-T Cells | unknown | N/A | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT04052152 | Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 9, 2019 | clinicaltrials |
| NCT03598179 | XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects | unknown | Phase 2 | 10 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03815383 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 12 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT01670370 | Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL. | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Feb 15, 2019 | clinicaltrials |
| NCT01818908 | Trial of DA-EPOCH Regimen for NHL With HLH | unknown | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03795571 | Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL(R2-GOD) | unknown | Phase 1 | 12 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02879526 | Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma | unknown | Phase 2 | 45 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02767674 | Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma | unknown | Phase 3 | 258 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03766776 | Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)(ATAHC) | unknown | N/A | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Dec 11, 2018 | clinicaltrials |
| NCT03724591 | Total Mesorectum Excision With Left Colic Artery Preservation for the Treatment of Rectal Cancer | unknown | N/A | 600 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Oct 30, 2018 | clinicaltrials |
| NCT03700333 | Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC | unknown | Phase 3 | 120 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Oct 9, 2018 | clinicaltrials |
| NCT03650738 | This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 29, 2018 | clinicaltrials |
| NCT03443921 | Divestment for Artery-involved Pancreatic Cancer | unknown | N/A | 122 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT03329495 | Laparoscopic Right Hemicoloectomy for Right Colon Cancer With a Medial-to-lateral Approach Orientated by SMA or SMV | unknown | Phase 2 / Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02912052 | Perioperative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis(PEPCORLI) | unknown | Phase 3 | 240 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 23, 2016 | clinicaltrials |
| NCT02882269 | Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer | unknown | Phase 2 / Phase 3 | 400 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 30, 2016 | clinicaltrials |
| NCT02644148 | Uncut Roux-en-Y Gastrojejunostomy for Early Gastric Cancer Patients | unknown | Phase 2 | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 11, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials